Lupin Announces U.S. FDA Approval and Launch of Sugammadex Injection

Global pharma major Lupin Limited (Lupin) today announced that following approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application, the company launched Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vial in the United States.

Lupin's Sugammadex Injection is the bioequivalent to Bridion® Injection of Merck, Sharp & Dohme LLC (Merck) and is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery.

Shares of Lupin Limited was last trading in BSE at Rs. 2413.95 as compared to the previous close of Rs. 2419.10. The total number of shares traded during the day was 30934 in over 2136 trades.

The stock hit an intraday high of Rs. 2433.70 and intraday low of 2405.00. The net turnover during the day was Rs. 74799387.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals USFDA Approval SugammadexInjection